Company: SION
Filing Date: 2025-08-11
Form Type: 10-Q
Source: 0002036042-25-000047
Chunk: 310

Company: Sionna Therapeutics, Inc.
Filing Date: 2025-08-11
Form: 10-Q
Item: Part I, Item 1
Chunk 310
---
221,479 146 (39)221,586 Marketable securities, noncurrent:U.S. Treasury securities61,168 78 (1)61,245 Government agency securities13,455 2 (3)13,454 Total marketable securities, noncurrent74,623 80 (4)74,699 Total marketable securities$296,102 $226 $(43)$296,285 December 31, 2024Amortized Cost Unrealized Gain Unrealized Loss Fair Value Marketable securities, current:U.S. Treasury securities$55,154 $176 $— $55,330 Government agency securities31,198 62 (1)31,259 Corporate debt17,205 22 — 17,227 Commercial paper5,931 3 — 5,934 Total marketable securities, current109,488 263 (1)109,750 Marketable securities, noncurrent:U.S. Treasury securities15,266 83 — 15,349 Government agency securities5,133 23 — 5,156 Total marketable securities, noncurrent20,399 106 — 20,505 Total marketable securities$129,887 $369 $(1)$130,255 The Company has determined that there were no material changes in the credit risk, therefore the Company has not recognized any allowance for credit losses on its debt securities. As of June 30, 2025, the Company holds marketable securities with an aggregate fair value of $74.7 million that had remaining maturities between one and two years. All other securities had a contractual maturity of less than a year. There were no realized gains or losses during the three and six months ended June 30, 2025, or 2024.

F-9

4. Fair Value Measurements 

The following tables present information about the Company’s financial instruments that are measured at fair value on a recurring basis and indicates the fair value hierarchy of the inputs the Company utilized to determine such fair value (in thousands): June 30, 2025Total Level 1 Level 2 Level 3 AssetsCash equivalents:Money market funds$40,485 $40,485 $— $— Marketable securities:U.S. Treasury securities183,705 183,705 — — Commercial paper61,638 — 61,